Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Influence of social contact patterns and demographic factors on influenza simulation results

Authors: Ruprecht Schmidt-Ott, Markus Schwehm, Martin Eichner

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

The demographic composition and the frequency and nature of social contacts may affect the spread of influenza virus in a population, resulting in distinct age-dependent immunity patterns. As demography and social contact rates differ strongly between European countries, this may impact infection incidence and vaccine effectiveness and thus limit the extent to which conclusions derived from observations in one country can be generalized to others. In the current study, we aimed to decipher the impact of social contact patterns and demographic factors on simulation results and, thus, to determine to what extent vaccination results can be generalized.

Methods

We simulated the transmission of four influenza strains (A(H1N1), A(H3N2), B/Victoria, B/Yamagata) in Belgium, Finland, Germany, GB, Italy, Luxembourg, Netherlands and Poland, using the simulation tool 4Flu. Individuals were connected in a dynamically evolving age-dependent contact network based on the POLYMOD study.

Results

When averaged over 20 years, simulation results without vaccination ranged from annually 20,984 (Germany) to 31,322 infections (Italy) per 100,000 individuals. QIV annually prevented 1758 (Poland) to 7720 infections (Germany) per 100,000. Variability of prevented cases remained high when the country-specific vaccination was replaced by unified coverage, but was reduced considerably if the same demography was used for all countries, or even more so when the same contact matrix was used.

Conclusions

Contact matrix and demography strongly influence the age-dependent incidence of influenza and the success of vaccination. Projecting simulation results from one country to another can, therefore, lead to erroneous results.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol. 2006;164(10):936–44.CrossRefPubMed Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol. 2006;164(10):936–44.CrossRefPubMed
4.
go back to reference Eichner M, et al. 4Flu—an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365.CrossRefPubMedPubMedCentral Eichner M, et al. 4Flu—an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365.CrossRefPubMedPubMedCentral
5.
go back to reference Dolk C, et al. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics. 2016. [Epub ahead of print]. Dolk C, et al. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics. 2016. [Epub ahead of print].
6.
go back to reference Baguelin M, et al. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013;10(10):e1001527.CrossRefPubMedPubMedCentral Baguelin M, et al. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013;10(10):e1001527.CrossRefPubMedPubMedCentral
8.
go back to reference Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010;26(2):183–91.CrossRefPubMed Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010;26(2):183–91.CrossRefPubMed
10.
11.
13.
go back to reference Vynnycky E, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30.CrossRefPubMed Vynnycky E, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30.CrossRefPubMed
14.
go back to reference Jefferson T, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;8:CD004879. Jefferson T, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;8:CD004879.
15.
go back to reference Jefferson T, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269. Jefferson T, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269.
17.
go back to reference Blank PR, Szucs TD. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Rev Vaccines. 2009;8(4):425–33.CrossRefPubMed Blank PR, Szucs TD. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Rev Vaccines. 2009;8(4):425–33.CrossRefPubMed
23.
go back to reference Postma MJ, et al. Economic evaluation of influenza vaccination. Assessment for The Netherlands. Pharmacoeconomics. 1999;16 Suppl 1:33–40.CrossRefPubMed Postma MJ, et al. Economic evaluation of influenza vaccination. Assessment for The Netherlands. Pharmacoeconomics. 1999;16 Suppl 1:33–40.CrossRefPubMed
Metadata
Title
Influence of social contact patterns and demographic factors on influenza simulation results
Authors
Ruprecht Schmidt-Ott
Markus Schwehm
Martin Eichner
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1981-5

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.